Sarepta Announces Favorable Safety Results from Phase I Influenza Drug Candidate; BioCryst Declared The NIAID Exercised Two Alternatives For GMP Drug Print E-mail
By Marilyn Mullen   
Thursday, 02 October 2014 19:26
Below is a look at some of the headlines for companies that made news in the healthcare sector on October 2, 2014.
Sarepta Therapeutics, Inc., (NASDAQ:SRPT)  21.63 -0.25 (-1.14%), declared positive safety results on Tuesday by the separate dose portion of a Phase I study of its lead influenza treatment candidate.

The test of the treatment, called AVI-7100, is being conducted in partnership between the Sarepta Therapeutics and the National Institute of Allergy and Infectious Diseases (NIAID).

The separate dose portion of the Phase I analyze in forty able-bodied volunteers in either live or placebo cohorts. The final result* showed that AVI-7100 was well endured with no clinically important harmful effects. An nonpartisan data and safety supervising board went over the results of the study and urged it carry on as planned.

The treatment employs Sarepta Therapeutics’ PMOplus chemistry, which is also the basis of the company’s clinical-stage Ebola and Marburg drug candidates. Sarepta spokespersons conveyed optimism that additional collaborative work with the NIH and NIAID using PMOplus will bring about additional treatments for dangerous diseases.

“The similar drug-like characteristics demonstrated across a broad spectrum of targets offers a versatility that will be especially critical in developing a capability to rapidly respond and adapt to real-world, global health threats – whether that is an Ebola outbreak, an influenza pandemic, or a never-before-seen emerging infectious disease,” Chris Garabedian, the president and CEO of Sarepta Therapeutics, said.



BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) declared that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised two other alternatives under its contract, which allows for GMP drug substance and drug product manufacture of BCX4430. Exercising  these options includes up to a $2.0 million growth to the existing development contract.

At the end of the trading day BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) moved up 3.78% to close at $10.15. BCRX is -30.57% away from its 52 week high and is moving 123.08% ahead of its 52 week low. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) return on investment (ROI) is -106.20% while return on equity (ROE) is -175.80%.

Also Thursday:

Bacterin International Holdings, Inc. (NYSE:BONE) today announced its CEO Dan Goldberger will be a guest on FOX Business Network's Opening Bell with Maria Bartiromo at approximately 10:40 AM/ET on Friday, October 3, 2014.

Curis, Inc. (Nasdaq:CRIS)
, an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today announced advances in the development of CUDC-907, its oral, dual inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) enzymes that is currently under investigation in a first-in-human single agent trial in patients with relapsed/refractory lymphomas or multiple myeloma.

Dehaier Medical Systems Ltd. (Nasdaq:DHRM)
which develops, assembles, markets and sells medical devices and wearable sleep respiratory products in China, today announced that twenty-eight medical examination centers and hospitals in China have introduced Dehaier's wearable sleep respiratory technology systems to provide Obstructive Sleep Apnea Syndrome ("OSAS") diagnosis, CPAP treatment, curative effect evaluation and other related services.

Durata Therapeutics (Nasdaq:DRTX)
today announced that it will present five posters highlighting data from its recently launched product, DALVANCE™ (dalbavancin) for injection, at IDWeek 2014, which takes place from October 8-11, 2014 in Philadelphia, PA.

EHouse Global, Inc. (OTCBB:EHOS)
, an emerging specialty nutraceutical company with 16 liquid based nutritional products in the dietary supplement industry, is pleased to report their 3rd Quarter Review 2014 to its shareholders and prospective investors.

Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, announced today that it was selected by Boston Dynamics, now part of Google, to continue developing technologies for Defense Advanced Research Projects Agency's (DARPA's) Warrior Web Task A project.

Five Prime Therapeutics, Inc. (Nasdaq:FPRX)
, a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced the appointment of Bill Ringo, a strategic advisor at Sofinnova Ventures, to the company's Board of Directors.

FutureWorld Corp. (OTCQB: FWDG), a leading provider of advanced technologies and solutions to the global cannabis industry, announces major traction of its recently launched affordable PersonalAnalytics Cannabis THC & CBD test kits. PersonalAnalytics test kits are the world's first ever affordable home testing kits for potency of cannabis cannabinoids (THC & CBD).

Heat Biologics, Inc. (Nasdaq:HTBX)
, a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today that it has dosed the ninth and final patient required in the Phase 1 portion of its Phase 1/2 clinical study for Vesigenurtacel-L (HS-410) in patients with high-risk non-muscle invasive bladder cancer.

Immune Design (Nasdaq:IMDZ)
announced today that the company was added to the Russell 2000® Index as part of Russell Investments' quarterly addition of select initial public offering (IPO) companies. Immune Design joined the index after the NASDAQ market closed on September 30, 2014.

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) today announced that its board of directors unanimously decided to appoint the company's founder, Dr. Horst G. Zerbe, as President and Chief Executive Officer.

MedAssets (Nasdaq:MDAS)
today announced that AHMC Healthcare Inc., and Alhambra Hospital and Medical Center has expanded its relationship with the company in pursuit of a rational and defensible pricing strategy.

Medical Marijuana Inc. (OTC Pink:MJNA)
, a leading cannabis and industrial hemp industry innovator, today announced the release of its quarterly financial and shareholders report (Post 09/30/2014 - OTC Markets).

Merit Medical Systems, Inc. (Nasdaq:MMSI)
, a leading manufacturer and marketer of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology, radiology and endoscopy, announced today that the Company will release its financial results for the third quarter ended September 30, 2014, after the close of the stock market on Thursday, October 23rd, 2014.

Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA)
, a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will host a live webcast of its 2014 R&D Day for investors and analysts on Friday, October 10, 2014 in New York City.

Nature's Sunshine Products, Inc. (Nasdaq:NATR)
, a leading natural health and wellness company engaged in the manufacture and direct sale of premium-quality nutritional and personal care products, today announced the appointment of Dr. William J. Keller to the company's Medical and Scientific Advisory Board.

NeoStem, Inc. (Nasdaq:NBS)
, a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), will present at multiple upcoming conferences in October.

Novadaq® Technologies Inc. (Nasdaq:NVDQ) (TSX:NDQ)
, the leading developer and provider of clinically relevant fluorescence imaging solutions for use in surgical and diagnostic procedures, today announced that final results from the PILLAR™II study, Perfusion Assessment in Laparoscopic Left Anterior Resection, were published ahead of print online by the Journal of the American College of Surgeons ("JACS"), the official scientific publication of the American College of Surgeons. In addition, results of a trial conducted in patients undergoing esophagectomy with a gastric pull up reconstruction conducted at the University of Southern California, was published ahead of print online by the Annals of Surgery ("Annals").

Scottsdale Lincoln Health Network (SLHN), one of Arizona's most respected non-profit health systems, has partnered with Premier, Inc. (Nasdaq:PINC) to further integrate care delivery in its evolution to a population health provider.

Protea Biosciences Group, Inc. (OTCQB:PRGB)
and InSphero AG jointly announced today an update from their collaboration focused on mass spectrometry imaging of InSphero's 3D InSight™ microtissues.

Radius Health, Inc. (Nasdaq:RDUS)
, a science-driven biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, announced today that it has priced its public offering of 2,750,000 shares of its common stock at a public offering price of $18.25 per share.

Sanomedics International Holdings, Inc. (OTCQB:SIMH)
, a medical technology holding company that focuses on providing game changing products, services and ideas, announced today that as flu season approaches, its Thermomedics, Inc. division is seeing increasing interest among Novation's network of hospitals for its Caregiver® TouchFree™ Clinical Thermometers. 

Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it has achieved a development milestone supporting a $1.5 million payment from Monsanto, following completion of specified program objectives.

Vascular Solutions, Inc. (Nasdaq:VASC)
today announced that it will host a live webcast of its third quarter conference call on Tuesday, October 21 at 3:30pm CST. Vascular Solutions' Chief Executive Officer, Howard Root, Chief Financial Officer, James Hennen and VP of Corporate Development, Phil Nalbone, will discuss the company's third quarter results.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus